Mr. Peter Whitehead reports

LIGHT AI TRADING ON THE OTCQB MARKET UNDER SYMBOL OHCFF

Light AI Inc. has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. Effective on April 7, 2025, common shares of Light AI began trading on the OTCQB under the symbol OHCFF and continued to trade on the Cboe Canada exchange under the symbol ALGO and on the Frankfurt Stock Exchange under the symbol 0HC.

The OTCQB allows established international companies listed on a qualified foreign exchange to leverage their existing reporting standards and make disclosures available in the United States -- utilizing the exemption from registration under Section 12(g) of the U.S. Securities Exchange Act of 1934, as amended, provided by Rule 12g3-2(b). Under exchange act Rule 12g3-2(b), international companies are exempt from SEC (U.S. Securities and Exchange Commission) registration and reporting if they are a foreign private issuer (as defined in exchange act 3b-4) and make whatever information is required by their home market regulator publicly available to U.S. investors in English. To qualify for the OTCQB, companies must be current in their reporting obligations, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

The Depository Trust Company (DTC) is a depository for securities and facilitates electronic settlement of transfers in the United States. The company also announces that it has been granted DTC eligibility for the trading of its shares in the U.S. DTC eligibility will help enhance the company's potential investor base and offer a more convenient trading experience for current and future shareholders.

"Accessing the OTCQB with DTC eligibility enables Light AI to expand its access to U.S. investors," said Peter Whitehead, chief executive officer of Light AI. "Given the company's global market opportunity, we believe cross-trading between Cboe, OTCQB and FSE will enhance liquidity and our commitment to delivering value for our shareholders."

For U.S. investors, current financial disclosure and real-time Level 2 quotes for the company are accessible on the OTC Markets website.

Engagement of investor relations service provider

The company also announces that it has engaged the investor relations services of Commodity Partners Inc. to provide capital markets and investor relations advisory services pursuant to an agreement dated Feb. 14, 2025. In exchange for providing IR services to the company, Commodity Partners will receive monthly payments up to an aggregate of $120,000. The agreement is for a one-year term commencing on approximately Feb. 14, 2025. Commodity Partners has an arm's-length relationship with the company.

About Light AI Inc.

Light AI is a health care company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of Strep A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving health care delivery worldwide. Its cutting-edge AI-powered technology offers rapid, accurate and cost-effective diagnostic tools designed to address critical health care challenges.

In pre-FDA (U.S. Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1-trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

We seek Safe Harbor.